---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-059557"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T04:24:57.123431+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics doses first patient in Phase 1/2a trial of PSV359 for FAP-α positive solid tumors

## Summary
- First patient dosed with [212Pb]PSV359 in Phase 1/2a dose-finding trial for FAP-α positive solid tumors.
- Patients selected via SPECT imaging with [203Pb]PSV359 to identify FAP-α expression.
- Trial aims to determine safety and preliminary anti-tumor activity; dose selection for monotherapy or combination.
- PSV359 construct optimized for tumor uptake, retention, and fast clearance from healthy tissues.

## SEC filing metadata
- accession: 0000950170-25-059557
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025059557/0000950170-25-059557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025059557/catx-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-059557
- JSON: https://secwatch.observer/filing/0000950170-25-059557.json
- Plain text: https://secwatch.observer/filing/0000950170-25-059557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.